Date: 2015-07-01
Type of information: IPO
Company: Seres Therapeutics (USA - MA)
Investors:
Amount: $139.8 million
Funding type: IPO
Planned used:
Others: * On July 1, 2015, Seres Therapeutics announced the closing of its initial public offering of 8,545,138 shares of its common stock at an initial public offering price of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,114,583 additional shares of common stock. The shares began trading on the NASDAQ Global Select Market under the ticker symbol \"MCRB\" on June 26, 2015. All of the shares of common stock in the offering were offered by the company. The net proceeds to Seres Therapeutics from the sale of shares in the offering are estimated to be approximately $139.8 million, after deducting the underwriting discounts and estimated offering expenses. * On June 25, 2015, Seres Therapeutics announced the pricing of its initial public offering of 7,430,555 shares of common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Seres Therapeutics. In addition, Seres Therapeutics granted the underwriters a 30-day option to purchase up to an additional 1,114,583 shares of common stock from the company at the public offering price. Goldman, Sachs & Co. and BofA Merrill Lynch are acting as joint book-running managers for the offering, and Leerink Partners and Canaccord Genuity Inc. are acting as lead managers for the offering.
Therapeutic area: Metabolic diseases - Digestive diseases - Infectious diseases
